ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
When Testosterone Is Not Enough
Beyond ED: cGMP-Specific PDE5i for Other Clinical Disorders
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 242786" data-attributes="member: 13851"><p><strong>Figure 6 <u>Role of novel inhibitors targeting cGMP-PKG in the treatment of AD</u>. Intracellular amyloid plaques consisting of Aβ aggregates and extracellular neurofibrillary tangles are formed by hyperphosphorylated tau fibrils, which affect neuronal functioning in AD. PDE5 inhibitors may attenuate neuronal apoptosis through the inhibition of neuroplasticity-related molecules, including BDNF and Aβ peptide. Novel compounds 1 and 3 are PDE5-specific inhibitors and can readily cross the blood-brain barrier with enhanced efficacy in mouse models of AD. Compound CM-414, a dual inhibitor of HDACs and PDE5, has synergistic therapeutic efficacy in AD models. Compounds 5 and 6 are also dual inhibitors that target both PDE5 and HDACs in AD. Compounds 7–9 are dual inhibitors of AChE and PDE5. Abbreviations: Aβ, amyloid-β; AChE, acetylcholine esterase; AD, Alzheimer’s disease; BDNF, brain-derived neurotrophic factor; cGMP, cyclic guanosine monophosphate; GSK3β, glycogen synthase kinase-3β; GTP, guanosine triphosphate; HDAC, histone deacetylase; pCREB, phosphorylated cAMP-response element binding protein; PDE5, phosphodiesterase 5; PDE5i, PDE5 inhibitor; pGC, particulate guanylate cyclase; PKG, protein kinase G; sGC, soluble guanylate cyclase.</strong></p><p><strong>[ATTACH=full]28311[/ATTACH]</strong></p></blockquote><p></p>
[QUOTE="madman, post: 242786, member: 13851"] [B]Figure 6 [U]Role of novel inhibitors targeting cGMP-PKG in the treatment of AD[/U]. Intracellular amyloid plaques consisting of Aβ aggregates and extracellular neurofibrillary tangles are formed by hyperphosphorylated tau fibrils, which affect neuronal functioning in AD. PDE5 inhibitors may attenuate neuronal apoptosis through the inhibition of neuroplasticity-related molecules, including BDNF and Aβ peptide. Novel compounds 1 and 3 are PDE5-specific inhibitors and can readily cross the blood-brain barrier with enhanced efficacy in mouse models of AD. Compound CM-414, a dual inhibitor of HDACs and PDE5, has synergistic therapeutic efficacy in AD models. Compounds 5 and 6 are also dual inhibitors that target both PDE5 and HDACs in AD. Compounds 7–9 are dual inhibitors of AChE and PDE5. Abbreviations: Aβ, amyloid-β; AChE, acetylcholine esterase; AD, Alzheimer’s disease; BDNF, brain-derived neurotrophic factor; cGMP, cyclic guanosine monophosphate; GSK3β, glycogen synthase kinase-3β; GTP, guanosine triphosphate; HDAC, histone deacetylase; pCREB, phosphorylated cAMP-response element binding protein; PDE5, phosphodiesterase 5; PDE5i, PDE5 inhibitor; pGC, particulate guanylate cyclase; PKG, protein kinase G; sGC, soluble guanylate cyclase. [ATTACH type="full"]28311[/ATTACH][/B] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
When Testosterone Is Not Enough
Beyond ED: cGMP-Specific PDE5i for Other Clinical Disorders
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top